Bloomberg reported that Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) rejected a $3.5 billion acquisition offer from Bristol-Myers Squibb Co. (NYSE: BMY). Shares of Amylin leaped $8.38 to close at $23.77 while Bristol-Myers stock held steady at $33.67.
Amylin Rejects Bristol-Myers' Offer
March 28, 2012 at 17:49 PM EDT
